HµRELflowTM
The metabolic competency of HµREL®‘s patented flow-based (i.e., perfusion-based) biochips and instrumentation enables parent compound clearance and metabolite generation significantly greater than that afforded by hepatocytes cultured under static conditions, when presented to compounds that invoke the broad range of Phase I and Phase II metabolic enzymes. HµREL®‘s flow-based metabolic competency has been shown stable for 14 days and longer.
U.S. Patent No’s. 5,612,188; 7,288,405; 8,030,061; other patents pending
technologyhurelflowpic

HµRELToxTM
multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
HµRELviralTM
Long-enduring infectious liver disease platform
Time-Based
Toxicity Ratios*
A new marker for hepatotoxic chronicity

TAAP
*patent pending
HµRELfluxTM
a new, patent-pending
efflux transport
assay method
DMPK
Superior intrinsic clearance
and biotransformation of
low-turnover drugs

DMD